A Phase I/II Study of Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Carfilzomib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- 19 Jul 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 19 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Jun 2016 Study design changed from single group assignment to parallel assignment; Treatment arm changed from 1 to 3.